Last Update 06 Feb 26

Fair value Increased 1.36%

REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating

Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple.

Analyst Commentary

Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window. The updates span both fresh initiations and long standing coverage, and they generally point to confidence in the company’s ability to execute on its core franchises while advancing its broader pipeline.

Several large firms, including JPMorgan, Goldman Sachs and Citi, have published higher price targets, while others have reiterated constructive views even when fine tuning their models. Taken together, these moves frame a research backdrop that is supportive of the higher fair value estimate, even if individual analysts differ on how much upside they see from current levels.

New coverage from HSBC and Truist adds further depth to the Street’s work on Regeneron. HSBC highlights the debate around how long growth can be sustained, while flagging nearer term drivers such as Eylea HD uptake and potential oncology milestones in 2026. Truist points to a combination of a broad commercial base, an R&D driven pipeline approach and a strong balance sheet as key elements of the long term equity story.

At the same time, not every research outlet is outright bullish on the shares. Scotiabank, for example, starts Regeneron at Sector Perform with a US$650 price target, reflecting a more balanced stance relative to the more optimistic targets above US$800 from other firms. For investors, this mix of views underlines that position sizing and risk tolerance still matter, even when the Street tone is generally constructive.

Bullish Takeaways

Multiple bullish analysts have moved price targets sharply higher, with Citi lifting its target to US$900 from US$700 and JPMorgan, Goldman Sachs and others also publishing higher levels. This supports a view that recent execution and pipeline progress are being reflected more fully in valuation models.
Goldman Sachs raises its target to US$914 from US$807 and links its stance to what it sees as improving fundamentals for the sector. If this trend is sustained, it could help support Regeneron’s P/E multiple relative to peers.
HSBC’s initiation at US$890 and Truist’s assumed coverage with a target of US$798 highlight confidence in the durability of core franchises such as Eylea, Dupixent and Libtayo. They also point to what they describe as long term growth optionality supported by the company’s technology platform and balance sheet.
A series of incremental target increases from bullish analysts, including large upward moves of US$100 or more, indicate that Street models are being recalibrated to higher revenue and earnings trajectories. This feeds into the higher consolidated fair value estimate of US$1,009.20.

What's in the News

The U.S. FDA approved EYLEA HD Injection 8 mg for macular edema following retinal vein occlusion, with dosing up to every 8 weeks after a monthly loading period, and added a monthly dosing option across wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion indications (Key Developments).
Regeneron and Sanofi reported upcoming Angiogenesis meeting presentations, including long-term QUASAR Phase 3 data for EYLEA HD in retinal vein occlusion through 64 weeks and first full primary data from the ELARA Phase 3b trial in wet age-related macular degeneration and diabetic macular edema, covering both extended and monthly dosing regimens (Key Developments).
Libtayo secured approval in cutaneous squamous cell carcinoma in the adjuvant setting, backed by the Phase 3 C POST trial, where it was reported as the first immunotherapy to significantly improve disease-free survival and reduce risk of recurrence or death by 68% in this setting (Key Developments).
Dupixent gained European Commission approval as a first-line targeted treatment option for moderate to severe chronic spontaneous urticaria in patients 12 years and older who do not respond adequately to antihistamines and are naive to anti-IgE therapy, supported by three Phase 3 LIBERTY CUPID trials (Key Developments).
Regeneron entered a global collaboration with Tessera Therapeutics to develop and commercialize TSRA 196, an in vivo Gene Writing program for alpha-1 antitrypsin deficiency, an inherited disease affecting lungs and liver in an estimated 200,000 people across the U.S. and Europe (Key Developments).

Valuation Changes

The Fair Value Estimate has risen slightly to US$1,009.20 from US$995.67, reflecting modest model tweaks across key inputs.
The Discount Rate has edged up slightly to 7.13% from 7.12%, a small change that has a limited impact on the updated valuation.
Revenue Growth has been marked higher to 13.15% from 10.53%, indicating more optimistic assumptions for future top line expansion in the model.
The Net Profit Margin has been trimmed to 34.82% from 36.52%, suggesting the updated work assumes a bit more cost pressure or mix shift over time.
The Future P/E has eased slightly to 15.44x from 15.68x, indicating a marginally lower valuation multiple applied to projected earnings.

10 views

Key Takeaways

Regeneron's best-in-class therapies, strong product adoption, and innovative pipeline position it for rapid market share gains and expanded, diversified long-term growth.
Strategic investments in manufacturing and advanced biologics platforms enable operational efficiency, robust supply, and capitalize on rising global demand for precision medicines.
Heavy dependence on key drugs and mounting biosimilar competition, payer pressure, and high R&D spending threaten revenue stability and future earnings growth.

Catalysts

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.What are the underlying business or industry changes driving this perspective?

While analyst consensus expects Dupixent's label expansions to steadily expand revenues, there is substantial evidence that Dupixent's best-in-class efficacy and unique safety profile across multiple, highly prevalent Type 2 inflammatory diseases-combined with market under-penetration and rapid initial uptake in recent launches-could yield a much steeper ramp in both US and global market share, supporting significantly higher long-term revenue and earnings growth.
Although analysts broadly agree that EYLEA HD's upcoming label enhancements and monthly dosing should solidify its position, they may be underestimating EYLEA HD's potential to rapidly capture a dominant branded share in the expanding retinal disease market, particularly given strong early adoption, robust product profile, and expected resolution of manufacturing bottlenecks, which could drive margin and revenue expansion well beyond current projections.
Regeneron's emerging portfolio in hematology and oncology-most notably Lynozyfic and odronextamab, each demonstrating best-in-class efficacy and safety with potential for use in earlier disease settings-positions the company to unlock multi-billion dollar opportunities in large, underserved populations like multiple myeloma and lymphoma, diversifying the revenue base at a time when industry standards of care are shifting toward advanced biologics.
Continued aggressive investment in U.S. manufacturing infrastructure, including a new state-of-the-art fill/finish facility and expanded biologics capacity, is likely to generate long-term operational advantages, enabling faster global launches, improved supply reliability, and sustainable improvements to gross and net margins as advanced therapies become a greater share of the portfolio.
Regeneron's leadership in antibody, siRNA, and genetic medicines-coupled with first-mover advantage in combining these advanced platforms-aligns with the accelerating global adoption of precision and personalized therapeutics, which will expand addressable markets as the aging population and rising chronic disease prevalence worldwide fuel higher, stickier demand for next-generation biologics, substantially boosting top-line growth over the next decade.

Regeneron Pharmaceuticals Earnings and Revenue Growth

Regeneron Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Regeneron Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Regeneron Pharmaceuticals's revenue will grow by 7.9% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from 31.4% today to 34.7% in 3 years time.
The bullish analysts expect earnings to reach $6.2 billion (and earnings per share of $58.86) by about September 2028, up from $4.5 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 16.1x on those 2028 earnings, up from 12.9x today. This future PE is greater than the current PE for the US Biotechs industry at 15.3x.
Analysts expect the number of shares outstanding to decline by 3.63% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Regeneron Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Regeneron's heavy reliance on EYLEA and Dupixent for the majority of its revenue exposes it to significant risk from biosimilar competition and loss of U.S. or global pricing power in high-cost biologics, which could result in declining top-line revenue and compressed earnings as these products face market exclusivity erosion and payer pressure.
Ongoing global scrutiny of drug costs and reimbursement, especially for leading drugs like EYLEA and Dupixent, combined with increasing consolidation among payers and providers, threatens to drive lower prices and restrict formulary access, putting downward pressure on both revenue growth and net margins over the long term.
The rising prevalence of biosimilars in the anti-VEGF and immunology space, coupled with current branded share declines and physician demand pressures experienced by EYLEA, suggests intensified competition and continued unit erosion, risking future revenue streams from one of Regeneron's largest franchises.
Delays in regulatory approvals and manufacturing enhancements, as seen with EYLEA HD and pipeline assets due to third-party site issues, highlight the risk of slower commercial launches and missed revenue expectations, while mounting R&D and manufacturing expenditures may not be offset by sufficient new product wins, leading to margin compression.
Elevated research and development spending and ambitious pipeline expansion carry the risk of stagnating returns should clinical trial productivity slow or pivotal readouts underperform, as evidenced by Wall Street's skepticism on the commercial value of Regeneron's pipeline versus its high R&D investment, potentially resulting in weaker future earnings and lower valuation multiples.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Regeneron Pharmaceuticals is $890.0, which is the highest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Regeneron Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $890.0, and the most bearish reporting a price target of just $543.0.
In order for you to agree with the bullish analysts, you'd need to believe that by 2028, revenues will be $17.8 billion, earnings will come to $6.2 billion, and it would be trading on a PE ratio of 16.1x, assuming you use a discount rate of 6.8%.
Given the current share price of $556.53, the bullish analyst price target of $890.0 is 37.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Regeneron Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Dupixent And EYLEA Will Seize Expanding Global Markets